Home  /  Resource Library  /  Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged < 60 years: Long-term efficacy results of a retrospective multicentre study

Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged < 60 years: Long-term efficacy results of a retrospective multicentre study

Study investigated bendamustine and brentuximab vedotin for treatment of Hodgkin lymphoma.